Daniel J. Speciale
Chief Financial Officer
With nearly 20 years of financial leadership experience within the healthcare and pharmaceuticals industries, Daniel brings a wealth of knowledge in corporate finance, investor relations and strategic planning to Kindeva.
As Chief Financial Officer, Daniel is responsible for overseeing all financial functions across the organization, ensuring strong fiscal management, strategic investments and sustainable business expansion as Kindeva continues its significant growth trajectory.
Most recently, he served as Senior Vice President, Finance–Controller, and Chief Accounting Officer at Vantive, where he was instrumental in establishing the financial strategy during its separation from Baxter in a $3.8 billion sale to Carlyle. Prior to this, Daniel held senior financial roles at Mallinckrodt, including Senior Vice President, Finance and CFO of the Specialty Generics division, where he oversaw $800 million in annual revenue and led both the controllership and investor relations functions. He began his career in the assurance practice at PricewaterhouseCoopers LLP, providing him with a strong foundation in financial principles.
Daniel holds a Bachelor of Science in Accountancy and a Master of Accounting Science degree from the Gies College of Business at the University of Illinois Urbana-Champaign. His extensive experience across both public and private companies makes him a valuable asset in driving Kindeva’s continued growth and success.
How can Daniel help you?
-
Ensuring robust financial management and fiscal discipline to support Kindeva's operations.
-
Developing and executing strategic financial plans to facilitate sustainable business expansion and growth.
-
Optimizing operational efficiency and maximizing value for Kindeva's stakeholders through sound financial leadership.
-
Driving strategic investment decisions to support innovation and expand Kindeva's global footprint.
See who else is in the team
Discover a team with technical expertise and a passion for purpose, dedicated to helping you manufacture more tomorrows and transform the future of drug delivery.
